TZTobias R. Zahn

Tobias R. Zahn

*This is an algorithmically generated author record based on publicly available information.

Tobias R. Zahn has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Repurposing of losartan for treatment of epidermolysis bullosa

    by Tobias Zahn, Dimitra Kiritsi, Leena Bruckner-Tuderman

    Introduction & Objective Losartan, a well-established medication to treat hypertension, has shown promise for the treatment of dystrophic epidermolysis bullosa (DEB), a hereditary rare skin blistering disease with secondary scarring and fibrosis. In a mouse disease model of dystrophic EB, losartan reduced fibrotic scarring and prevented fusion of digits. Our objective is to generate additional required data on the benefit of losartan in the treatment of DEB. We aim to obtain regulatory approval for losartan for the treatment of DEB. Materials & Methods A multidisciplinary team of physicians, pharmacists and entrepreneurs has come together and bundled efforts in the start-up company Crowd Pharma. The new ‘virtual’ company is dedicated to repurpose losartan for the treatment of DEB. Results A ‘second-medical-use’ patent of losartan for the treatment of EB has been granted in Europe (pending in the US). A new pediatric, easy-to-swallow formulation of losartan as minitablet has been developed that is suited for treatment of DEB (patent pending).. A first clinical trial of losartan in EB, funded by patient organisation DEBRA, was successfully completed at the EB center in Freiburg in 2021. Orphan designation has been granted by regulatory agencies EMA and FDA, and protocol assistance / pre-IND advice procedures have been completed. Conclusions Currently available evidence of efficacy and safety of losartan for the treatment of DEB is not considered sufficient by regulatory agencies. A placebo-controlled randomized clinical trial is required, for which fundraising is ongoing.

  • Open Access

    Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial

    by Dimitra Kiritsi, Franziska Schauer, Stella Gewert, Katja Reineker, Antonia Reimer-Taschenbrecker, Agnes Schwieger-Briel, Hagen Ott, Claudia Schmoor, Olga Grishina, Dedee Murrell, et al.


  • Open Access

    Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program

    by Juan P. Barret, Fred Podmelle, Břetislav Lipový, Hans-Oliver Rennekampff, Hauke Schumann, Agnes Schwieger-Briel, Tobias R. Zahn, Hans-Robert Metelmann


  • Top Cited Papers
    Open Access

    Alzheimer's disease beta-amyloid peptides are released in association with exosomes

    by Lawrence Rajendran, Masanori Honsho, Tobias R. Zahn, Patrick Keller, Kathrin D. Geiger, Paul Verkade, Kai Simons

    We demonstrate the existence of double-valued linear (infinite) spinorial representations of the group of general coordinate transformations. We discuss the topology of the group of general coordinate transformations and its subgroups GA(nR), GL(n,R), SL(nr) for n = 2,3,4, and the existence of a double covering. We present the construction of band-spinor representations of GL(n,R) in terms of Harish-Chandra modules. It is suggested that hadrons interact with gravitation as band-spinors of that type. In the metric-affine extension of general relativity, the hadron intrinsic hypermomentum is minimally coupled to the connection, in addition to the coupling of the energy momentum tensor to the vierbeins. The relativistic conservation of intrinsic hypermomentum fits the observed regularities of hadrons: SU(6) (∼ spin independence), scaling, and complex-J trajectories. The latter correspond to volume-preserving deformations (confinement?) exciting rotational bands.


  • Open Access

    Dense Core Vesicle Dynamics in Caenorhabditis elegans Neurons and the Role of Kinesin UNC‐104

    by Tobias R. Zahn, Joseph K. Angleson, Margaret A. MacMorris, Erin Domke, Cindi Schwartz, John C. Hutton

    We have developed a model system in Caenorhabditis elegans to perform genetic and molecular analysis of peptidergic neurotransmission using green fluorescent protein (GFP)-tagged IDA-1. IDA-1 represents the nematode ortholog of the transmembrane proteins ICA512 and phogrin that are localized to dense core secretory vesicles (DCVs) of mammalian neuroendocrine tissues. IDA-1::GFP was expressed in a small subset of neurons and present in both axonal and dendritic extensions, where it was localized to small mobile vesicular elements that at the ultrastructural level corresponded to 50 nm electron-dense objects in the neuronal processes. The post-translational processing of IDA-1::GFP in transgenic worms was dependent on the neuropeptide proprotein convertase EGL-3, indicating that the protein was efficiently targeted to the peptidergic secretory pathway. Time-lapse epifluorescence microscopy of IDA-1::GFP revealed that DCVs moved in a saltatory and bidirectional manner. DCV velocity profiles exhibited multiple distinct peaks, suggesting the participation of multiple molecular motors with distinct properties. Differences between velocity profiles for axonal and dendritic processes furthermore suggested a polarized distribution of the molecular transport machinery. Study of a number of candidate mutants identified the kinesin UNC-104 (KIF1A) as the microtubule motor that is specifically responsible for anterograde axonal transport of DCVs at velocities of 1.6 μm/s−2.7 μm/s.


  • IDA-1, aCaenorhabditis elegans homolog of the diabetic autoantigens IA-2 and phogrin, is expressed in peptidergic neurons in the worm

    by Tobias R. Zahn, Margaret A. Macmorris, Weijia Dong, Robert Day, John C. Hutton

    The closely related mammalian proteins IA‐2 and phogrin are protein tyrosine phosphatase‐like receptor proteins spanning the membrane of dense core vesicles of neuroendocrine tissues. They are of interest as molecular components of the secretory machinery and as major targets of autoimmunity in type I diabetes mellitus. The Caenorhabditis elegans genome has a single copy of an IA‐2/phogrin homolog ida‐1 III (islet cell diabetic autoantigen), which encodes the ida‐1 (B0244.2) gene product as a series of 12 exons over a 10‐kb region of chromosome III. The full‐length sequence of the ida‐1 cDNA encoded a 767‐amino acid type 1 transmembrane protein of 87 kDa. The PTP catalytic site consensus sequence of IDA‐1, like IA‐2 and phogrin, diverged and would not be active. Expression of green fluorescent protein (GFP) under the ida‐1 gene promoter showed activity in a subset of around 30 neurons with sensory functions and the uv1 cells of the vulva in hermaphrodites. Males showed additional expression in male‐specific neurons. In situ experiments in rat brain showing the distribution of IA‐2 and phogrin suggested a complimentary and overlapping pattern compared with the proprotein convertases PC1 and PC2. In C. elegans, IDA‐1‐expressing cells comprised a subset of those expressing the PC2 homolog KPC‐2 (C51E3.7), consistent with IDA‐1 being a component of neuropeptide‐containing dense core vesicles. The results support the hypothesis that C. elegans IDA‐1 is the functional homolog of IA‐2 and phogrin in mammals. Analysis of the function of IDA‐1 should contribute to our understanding of the function of these proteins in signal transduction, vesicle locomotion, and exocytosis. J. Comp. Neurol. 429:127–143, 2001.


  • Molecular cloning of a pancreatic islet-specific glucose-6-phosphatase catalytic subunit-related protein.

    by S D Arden, T Zahn, S Steegers, S Webb, B Bergman, R M O'BRien, J C Hutton

    A pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP) was cloned using a subtractive cDNA expression cloning procedure from mouse insulinoma tissue. Two alternatively spliced variants that differed by the presence or absence of a 118-bp exon (exon IV) were detected in normal balb/c mice, diabetic ob/ob mice, and insulinoma tissue. The longer, 1901-bp full-length cDNA encoded a 355-amino acid protein (molecular weight 40,684) structurally related (50% overall identity) to the liver glucose-6-phosphatase and exhibited similar predicted transmembrane topology, conservation of catalytically important residues, and the presence of an endoplasmic reticulum retention signal. The shorter transcript encoded two possible open reading frames (ORFs), neither of which possessed His174, a residue thought to be the phosphoryl acceptor (Pan CJ, Lei KJ, Annabi B, Hemrika W, Chou JY: Transmembrane topology of glucose-6-phosphatase. J Biol Chem 273:6144-6148, 1998). Northern blot and reverse transcription-polymerase chain reaction analysis showed that the mRNA was highly expressed in pancreatic islets and expressed more in beta-cell lines than in an alpha-cell line. It was notably absent in tissues and cell lines of non-islet neuroendocrine origin, and no other major tissue source of the mRNA was found. During development, it was expressed in parallel with insulin mRNA. The mRNA was efficiently translated and glycosylated in an in vitro translation/membrane translocation system and readily transcribed into COS 1, HIT, and CHO cells using cytomegalovirus or Rous sarcoma virus promoters. Whereas the liver glucose-6-phosphatase showed activity in these transfection systems, the IGRP failed to show glucose phosphotransferase or phosphatase activity with p-nitrophenol phosphate, inorganic pyrophosphate, or a range of sugar phosphates hydrolyzed by the liver enzyme. While the metabolic function of the enzyme is not resolved, its remarkable tissue-specific expression warrants further investigation, as does its transcriptional regulation in conditions where glucose responsiveness of the pancreatic islet is altered.